Address
Email address
Phone number
https://protobios.comHome - Protobios | Precision biomarker developmentProtobios is at the forefront of harnessing immune intelligence to develop next-generation diagnostic biomarkers and immunotherapy drugs. Through advanced immunome analysis, we transform complex immune data into actionable insights that drive precision medicine forward.
Name
OÜ IndiPro
Registry code
11371231
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
10.04.2007 (19)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
70201 -
15 500 €
6 131 €
40%
-
170 322 €
0
Submitted
No tax arrears
4%
4%
| Owner | Representative | Beneficial owner | |
|---|---|---|---|
| Omanikukonto: TÕNIS TIMMUSK
| - | Board member | - |
| Kaia Palm
| 100% - 2 556.00 EUR | Board member | Direct ownership |
| Owner | Representative | Beneficial owner | |
|---|---|---|---|
| dxlabs OÜ 11503052 | 45% - 1 143.00 EUR | - | - |
| 2019 30.10.2020 | 2020 29.06.2021 | 2021 02.09.2022 | 2022 03.07.2023 | 2023 23.07.2024 | 2024 30.06.2025 | |
|---|---|---|---|---|---|---|
| Total Revenue | 0 € | 0 € | - | 5 000 € | 6 000 € | 15 500 € |
| Net profit (loss) for the period | -27 652 € | -5 285 € | 4 976 € | 78 € | 35 € | 6 131 € |
| Profit Margin | - | - | - | 2% | 1% | 40% |
| Current Assets | 136 004 € | 133 907 € | 107 234 € | 109 883 € | 108 496 € | 104 599 € |
| Fixed Assets | 38 531 € | 35 284 € | 68 655 € | 69 004 € | 68 646 € | 68 646 € |
| Total Assets | 174 535 € | 169 191 € | 175 889 € | 178 887 € | 177 142 € | 173 245 € |
| Current Liabilities | 147 € | 88 € | 1 810 € | 4 730 € | 2 951 € | 2 923 € |
| Non Current Liabilities | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Share Capital | - | - | - | - | - | - |
| Equity | 174 388 € | 169 103 € | 174 079 € | 174 157 € | 174 191 € | 170 322 € |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2025 Q4 | - | - | - | - |
| 2025 Q3 | - | 3 808 € | 0 € | - |
| 2025 Q2 | - | - | - | - |
| 2025 Q1 | - | - | - | - |
| 2024 Q4 | - | 2 500 € | 0 € | - |
| 2024 Q3 | - | - | - | - |
| 2024 Q2 | - | - | - | - |
| 2024 Q1 | - | - | - | - |
